Literature DB >> 7636471

Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: a mutational analysis.

A C Andeweg1, P H Boers, A D Osterhaus, M L Bosch.   

Abstract

Several studies have demonstrated a functional role for the V1-V2 region of the human immunodeficiency virus type 1 (HIV-1) envelope surface glycoprotein gp120 in the membrane fusion processes underlying viral entry and syncytium induction. In a study with chimeric primary envelope genes, we have previously demonstrated that the exchange of V2 regions was sufficient to transfer syncytium-inducing capacity to a non-syncytium-inducing envelope protein. The exchanged V2 regions, comprising a number of variable amino acids, conferred changes to both the predicted secondary structure and to the net positive charge of the V2 loops. In a syncytium-forming assay based on transient envelope protein expression in CD4+ SupT1 cells, we have extended this observation by mutating the variable positions of the V2 region to determine the relative contribution of individual amino acids to syncytium formation. It can be shown that simultaneous mutation of multiple amino acids is needed to interfere with the V2 region-determined syncytium-inducing phenotype. Single amino acid changes either influencing charge of predicted secondary structure of the V2 loop proved to be insufficient to abolish V2 region-controlled syncytium formation. This robust V2 organization may allow the virus to accumulate mutations, while retaining its biological phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636471     DOI: 10.1099/0022-1317-76-8-1901

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

2.  Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.

Authors:  D G Fox; P Balfe; C P Palmer; J C May; C Arnold; J A McKeating
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.

Authors:  B Etemad-Moghadam; G B Karlsson; M Halloran; Y Sun; D Schenten; M Fernandes; N L Letvin; J Sodroski
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.

Authors:  Q Shi; A T Nguyen; Y Angell; D Deng; C-R Na; K Burgess; D D Roberts; F C Brunicardi; N S Templeton
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

5.  Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-17

6.  Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Drug Deliv       Date:  2012-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.